PAncreatic Adenocarcinoma in Hospital (APACH)

March 11, 2022 updated by: Centre Hospitalier Departemental Vendee

Few data are currently available in the literature on pancreatic adenocarcinoma in France. About 8,000 new cases each year in France. The 5-year survival for all stages combined is <5%. This is the only digestive cancer in which mortality / incidence ratio is 98%.

Epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (FOLFIRINOX) are mispriced in real life.

The development of new drugs and the development of Phase II and III require a better understanding of the state of this disease in the country.

The main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in France and make an inventory of diagnostic practices and support.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

1204

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Jolimont, Belgium
        • CH de Jolimont
  • France
      • Aix en Provence, France, 13616
        • CHIAP
      • Angoulême, France
        • CH Angoulême
      • Aubenas, France, 07200
        • CH d'Aubenas
      • Auch, France, 32008
        • CH Auch
      • Aulnay sous bois, France
        • CH Robert Ballanger
      • Avignon, France
        • Ch Avignon
      • Bagnols sur Ceze, France
        • CH Bagnols sur Ceze
      • Bayeux, France, 14400
        • Ch Bayeux
      • Blois, France, 41016
        • CH BLOIS
      • Bourg en Bresse, France
        • CH Bourg en Bresse
      • Bourges, France, 18000
        • CH de Bourges
      • Bressuire, France
        • CH Nord Deux Sèvres
      • Bry sur Marne, France
        • CH Saint Camille
      • Béziers, France, 34500
        • CH Beziers
      • Castres, France, 81108
        • HPA Castres Mazamet
      • Chalons en champagne, France
        • CH Chalons En Champagne
      • Chambery, France
        • CH Chambery
      • Chartres, France, 28630
        • CH Chartres
      • Cholet, France
        • Ch Cholet
      • Château Gontier, France
        • CH Haut Anjou
      • Châteauroux, France, 36000
        • Ch Chateauroux
      • Compiègne, France
        • CH Compiègne Noyon
      • Corbeil Essonnes, France
        • CH SUd Francilien
      • Creil, France, 60109
        • CH de Creil
      • Créteil, France, 94000
        • CHI Creteil
      • Dourdan, France
        • CH Dourdan
      • Draguignan, France
        • CH Draguignan
      • Dreux, France, 28100
        • CH Dreux
      • Eaubonne, France, 95600
        • CH Simone VEIL
      • Ferolles, France
        • CH Forcilles
      • Gap, France
        • CHICAS
      • Gonesse, France, 95500
        • CH Gonesse
      • La Roche sur Yon, France, 85925
        • Centre Hospitalier Départemental Vendée
      • Lagny sur Marne, France, 77400
        • Centre Hospitalier de Lagny
      • Le Mans, France
        • CH du Mans
      • Lens, France
        • Lens
      • Les Sables d'Olonne, France, 85100
        • Centre Hospitalier Côté de lumière
      • Macon, France
        • Hôpital des chanaux
      • Meaux, France, 77100
        • Centre Hospitalier de Meaux
      • Melun, France
        • CH Melun
      • Metz, France
        • CHR de Mercy-Metz
      • Montargis, France, 45207
        • CHAM
      • Montauban, France
        • CH Montauban
      • Montelimar, France, 26200
        • Centre Hospitalier Montelimar
      • Montfermeil, France
        • Ch Montfermeil
      • Niort, France
        • CH Niort
      • Oloron Sainte Marie, France
        • CHG Oloron
      • Orléans, France, 45000
        • CHR Orleans
      • Pau, France
        • CH Francois Mitterand
      • Perpignan, France, 66046
        • Centre Hospitalier de Perpignan
      • Poissy, France, 78600
        • CHI Poissy Saint Germain
      • Pontoise, France
        • CH Pontoise
      • Pringy, France, 74374
        • CH de la Region d'Annecy
      • Quimper, France, 29107
        • CH Quimper
      • Roubaix, France
        • CH Roubaix
      • Saint Brieuc, France, 22200
        • Centre Hospitalier Yves Le Foll
      • Saint Quentin, France
        • CH Saint Quentin
      • Saint-Denis, France
        • CH de la Fontaine
      • Tarbes, France, 65013
        • Centre Hospitalier de Bigorre
      • Toulon, France
        • CH Sainte Musse
      • Tourcoing, France
        • Ch Tourcoing
      • Valenciennes, France
        • CH Valenciennes
      • Vannes, France, 56017
        • CHBA de Vannes
      • Villeneuve Saint-Georges, France, 94190
        • CHIV Villeneuve Saint-Georges
    • La Réunion
      • Saint-Paul, La Réunion, France, 97866
        • CH Gabriel Martin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patient in hepatogastroenterology in general hospital

Description

Inclusion Criteria:

  • Living in France
  • Pancreatic adenocarcinoma histologically or cytologically proven
  • primary diagnosis
  • Agreed to participate

Exclusion Criteria:

  • Suspected pancreatic adenocarcinoma histologically or cytologically unproven
  • Refused to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Pancreatic Adenocarcinoma

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Survival
Time Frame: patient death (following during 5 year)
patient death (following during 5 year)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Departemental Vendee

Investigators

  • Principal Investigator: Roger FAROUX, PH, Centre Hospitalier Départemental Vendée

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 18, 2013

Primary Completion (Actual)

December 4, 2015

Study Completion (Actual)

December 1, 2020

Study Registration Dates

First Submitted

November 6, 2013

First Submitted That Met QC Criteria

November 15, 2013

First Posted (Estimate)

November 21, 2013

Study Record Updates

Last Update Posted (Actual)

March 14, 2022

Last Update Submitted That Met QC Criteria

March 11, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHD064-13

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreatic Adenocarcinoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe